EA Series Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

EA Series Trust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$250K	Buy	+1,318	New	+$261K	0.01%	1014

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EA Series Trust's ALNY Position: Q2 2023 in Review

EA Series Trust opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2023: 1,318 shares worth $250K. The stake represents 0.01% of the portfolio and ranks #1014 among its holdings.

476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

EA Series Trust held 1,318 shares of Alnylam Pharmaceuticals worth $250K as of Q2 2023.
Alnylam Pharmaceuticals was a new EA Series Trust position in Q2 2023.
Alnylam Pharmaceuticals made up 0.01% of EA Series Trust's portfolio in Q2 2023, its #1014 holding.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.